MedPath

A feasibility study of concurrent chemotherapy using S-1 with stereotactic body radiation therapy for clinical stage I-IIA Non-small Cell Lung Cancer (LOGIK1602)

Phase 1
Conditions
non-small cell lung cancer
Registration Number
JPRN-UMIN000032693
Lead Sponsor
Clinical Research Support Center Kyushu
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
1
Inclusion Criteria

Not provided

Exclusion Criteria

1.Apparent interstitial pneumonitis and fibrosis 2.Active inflammation without oral drugs 3.Double cancer 4.Pregnancy 5.Psychiatric disorder 6.Steroid administration 7.Oxygen administration 8.Fever of 38.0 degrees centigrade or higher

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Completion Rate of S-1 administration & radiotherapy
Secondary Outcome Measures
NameTimeMethod
Adverse events, Grade 2 or greater radiation pneumonitis,Overall survival rate at 2 years, Disease-free survival rate at 2 years, Local control rate at 2 years
© Copyright 2025. All Rights Reserved by MedPath